CRISPR Therapeutics (CRSP) Competitors $40.72 +0.34 (+0.84%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRSP vs. NBIX, TECH, PCVX, QGEN, EXEL, RGEN, RVMD, HALO, KRYS, and ACLXShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Qiagen (QGEN), Exelixis (EXEL), Repligen (RGEN), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), and Arcellx (ACLX). These companies are all part of the "biological products, except diagnostic" industry. CRISPR Therapeutics vs. Neurocrine Biosciences Bio-Techne Vaxcyte Qiagen Exelixis Repligen Revolution Medicines Halozyme Therapeutics Krystal Biotech Arcellx Neurocrine Biosciences (NASDAQ:NBIX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Do institutionals and insiders believe in NBIX or CRSP? 92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor NBIX or CRSP? Neurocrine Biosciences received 543 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.39% of users gave Neurocrine Biosciences an outperform vote while only 64.83% of users gave CRISPR Therapeutics an outperform vote. CompanyUnderperformOutperformNeurocrine BiosciencesOutperform Votes101377.39% Underperform Votes29622.61% CRISPR TherapeuticsOutperform Votes47064.83% Underperform Votes25535.17% Does the media favor NBIX or CRSP? In the previous week, Neurocrine Biosciences had 27 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 35 mentions for Neurocrine Biosciences and 8 mentions for CRISPR Therapeutics. Neurocrine Biosciences' average media sentiment score of 0.67 beat CRISPR Therapeutics' score of 0.41 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 12 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger valuation and earnings, NBIX or CRSP? Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$1.89B7.27$249.70M$3.7336.31CRISPR Therapeutics$200M17.38-$153.61M-$2.83-14.39 Do analysts prefer NBIX or CRSP? Neurocrine Biosciences currently has a consensus price target of $166.00, suggesting a potential upside of 22.58%. CRISPR Therapeutics has a consensus price target of $77.93, suggesting a potential upside of 91.39%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83CRISPR Therapeutics 1 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has more risk & volatility, NBIX or CRSP? Neurocrine Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Is NBIX or CRSP more profitable? Neurocrine Biosciences has a net margin of 17.21% compared to CRISPR Therapeutics' net margin of -118.13%. Neurocrine Biosciences' return on equity of 15.68% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences17.21% 15.68% 11.38% CRISPR Therapeutics -118.13%-12.15%-10.35% SummaryNeurocrine Biosciences beats CRISPR Therapeutics on 16 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48B$2.94B$5.01B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-14.3945.94135.0717.15Price / Sales17.38411.851,120.63116.80Price / CashN/A182.1040.5837.88Price / Book1.723.894.754.78Net Income-$153.61M-$42.21M$118.50M$225.60M7 Day Performance-6.99%-2.14%-1.85%-1.21%1 Month Performance-11.96%4.21%11.28%3.09%1 Year Performance-32.81%18.39%29.92%16.48% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics2.5018 of 5 stars$40.72+0.8%$77.93+91.4%-33.0%$3.48B$200M-14.39473Analyst ForecastHigh Trading VolumeNBIXNeurocrine Biosciences4.8249 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsTECHBio-Techne4.6341 of 5 stars$76.51+1.1%$82.00+7.2%-3.5%$12.16B$1.17B81.073,100PCVXVaxcyte1.6049 of 5 stars$90.74+3.4%$147.50+62.6%+45.4%$11.31BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.7279 of 5 stars$45.47+0.2%$51.15+12.5%+3.1%$10.38B$1.97B117.035,967EXELExelixis4.5077 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0971 of 5 stars$160.33+2.5%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsRVMDRevolution Medicines4.5467 of 5 stars$45.000.0%$63.67+41.5%+71.5%$7.57B$11.58M-12.54443Insider TradeHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive NewsKRYSKrystal Biotech4.5152 of 5 stars$171.83+5.0%$206.67+20.3%+45.9%$4.94B$50.70M92.45229Analyst ForecastACLXArcellx3.1314 of 5 stars$85.05+1.5%$105.93+24.5%+49.1%$4.60B$155.82M-118.03130Positive News Related Companies and Tools Related Companies Neurocrine Biosciences Alternatives Bio-Techne Alternatives Vaxcyte Alternatives Qiagen Alternatives Exelixis Alternatives Repligen Alternatives Revolution Medicines Alternatives Halozyme Therapeutics Alternatives Krystal Biotech Alternatives Arcellx Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRSP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts